Too many white cells-TAM, JMML, or something else?

Area of Science:

• Pediatric Hematology
• Oncology
• Genetics

Background:

• Leukocytosis is common in children, with a differential diagnosis ranging from benign reactive causes to malignant myeloproliferative disorders.
• Transient abnormal myelopoiesis (TAM) is linked to trisomy 21 and GATA1 mutations, with variable outcomes.
• Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric myeloproliferative disorder involving RAS-pathway signaling.

Purpose of the Study:

• To discuss the presentation and evaluation of leukocytosis in pediatric patients.
• To review myeloproliferative disorders, including TAM and JMML, within the differential diagnosis of pediatric leukocytosis.
• To explore treatment strategies for these conditions.

Main Methods:

• Literature review of pediatric leukocytosis, focusing on myeloproliferative disorders.
• Analysis of clinical presentations and diagnostic criteria for TAM and JMML.
• Synthesis of current treatment approaches and management concepts.

Main Results:

• TAM and JMML represent significant causes of pediatric myeloproliferative disorders.
• Early identification of TAM and JMML is critical due to their potential for severe complications.
• Treatment strategies vary, with observation being suitable for some TAM patients and hematopoietic stem cell transplantation often indicated for JMML.

Conclusions:

• Clinicians must be aware of TAM and JMML when evaluating pediatric leukocytosis.
• A thorough understanding of these myeloproliferative disorders aids in timely diagnosis and appropriate management.
• Effective management hinges on recognizing specific presentations and understanding evolving treatment paradigms.